MannKind Corporation Stock Nasdaq
Stocks
US56400P2011
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 1.04B 932M 861M 780M 1.46B 98.65B 1.48B 10.32B 4.1B 51.71B 3.9B 3.82B 164B | P/E 2026 * |
-16.9x | P/E 2027 * | 1,455x |
|---|---|---|---|---|---|
| Enterprise Value | 1.04B 932M 861M 780M 1.46B 98.65B 1.48B 10.32B 4.1B 51.71B 3.9B 3.82B 164B | EV / Sales 2026 * |
2.35x | EV / Sales 2027 * | 2.05x |
| Free-Float |
98.53% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: MannKind Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 49 | 25/05/2017 |
| Director of Finance/CFO | 50 | 22/04/2024 | |
Ajay Ahuja
CTO | Chief Tech/Sci/R&D Officer | - | 29/09/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Ronald Consiglio
BRD | Director/Board Member | 82 | 01/10/2003 |
Michael Friedman
BRD | Director/Board Member | 82 | 01/12/2003 |
James Shannon
CHM | Chairman | 69 | 09/12/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.10% | -3.43% | +36.29% | +67.69% | 65.28B | |
| +0.33% | +0.33% | +10.16% | +78.07% | 54.57B | |
| +0.16% | +1.73% | +9.89% | +102.10% | 53.59B | |
| -0.20% | +1.85% | +25.47% | +51.61% | 45.03B | |
| -1.50% | -4.83% | +16.01% | +114.69% | 42.17B | |
| +1.61% | -5.17% | +221.42% | +901.56% | 39.42B | |
| -0.74% | -4.84% | +14.53% | +44.45% | 32.71B | |
| -2.70% | -7.34% | +23.17% | +0.36% | 24.01B | |
| +1.11% | +15.18% | +60.27% | +49.33% | 26.5B | |
| Average | -0.58% | +1.98% | +46.36% | +156.65% | 42.59B | |
| Weighted average by Cap. | -0.66% | +1.72% | +43.39% | +155.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 442M 397M 366M 332M 621M 41.97B 628M 4.39B 1.74B 22B 1.66B 1.62B 69.77B | 507M 455M 420M 381M 713M 48.19B 721M 5.04B 2B 25.26B 1.9B 1.86B 80.1B |
| Net income | -60.94M -54.69M -50.5M -45.8M -85.59M -5.79B -86.65M -605M -240M -3.03B -229M -224M -9.62B | 1.18M 1.06M 976K 885K 1.65M 112M 1.68M 11.71M 4.65M 58.66M 4.42M 4.33M 186M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
